Madrigal Pharmaceuticals
MDGL
Market cap $6.55B

300.52 USD

-38.39

11.33%

Updated Jan 13, 11:36 AM EST

1 day

-11.33%

5 days

-6.72%

1 month

-1.31%

3 months

39.50%

6 months

7.35%

Year to date

-4.23%

1 year

23.20%

5 years

245.35%

10 years

221.58%

About: Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Employees: 376

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,814 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

29% more call options, than puts

Call options by funds: $216M | Put options by funds: $168M

2% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 44

1% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 82

1% less funds holding

Funds holding: 255 [Q2] → 253 (-2) [Q3]

4.17% less ownership

Funds ownership: 108.59% [Q2] → 104.42% (-4.17%) [Q3]

26% less capital invested

Capital invested by funds: $6.48B [Q2] → $4.77B (-$1.71B) [Q3]

36% less funds holding in top 10

Funds holding in top 10: 14 [Q2] → 9 (-5) [Q3]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$236

21%

downside

Avg. target

$369

23%

upside

High target

$441

47%

upside

5 analyst ratings

4 positive

80%

1 neutral

20%

0 negative

0%

JMP Securities Jonathan Wolleben 41% 1-year accuracy 31 / 76 met price target	42%upside $427	Market Outperform Reiterated	10 Jan 2025
B. Riley Securities Mayank Mamtani 39% 1-year accuracy 9 / 23 met price target	21%downside $236	Neutral Maintained	5 Nov 2024
UBS Eliana Merle 37% 1-year accuracy 7 / 19 met price target	47%upside $441	Buy Maintained	1 Nov 2024
Oppenheimer Jay Olson 21% 1-year accuracy 21 / 102 met price target	16%upside $350	Outperform Maintained	23 Oct 2024
HC Wainwright & Co. Ed Arce 55% 1-year accuracy 83 / 152 met price target	30%upside $390	Buy Reiterated	22 Oct 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about MDGL published over the past 30 days

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

CONSHOHOCKEN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced an update on its business performance, including preliminary* fourth-quarter and year-end net sales, year-end cash and patients on Rezdiffra.

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion

Rezdiffra's strong launch has been confirmed by robust sales in the first two quarters, even though it may have only been used in 2% of its current target patient population. Competitors with MASH therapies like NVO, SGMT, ALT and Boehringer Ingelheim are making progress, although the possibility of combinations could limit any downside for MDGL. There is ongoing discussion about a potential buyout, adding another layer of interest for investors, and a potential EU launch in H2'25.

Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will take Accolade private.

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CONSHOHOCKEN, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PT. The presentation will be webcast live and can be accessed here or by visiting Madrigal's Investor Relations Site, Events and Presentations.

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Top 3 Health Care Stocks That May Dip This Month

As of Nov. 25, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks That May Dip This Month

The Motley Fool

3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move

When a company's shares shoot up 82% in 12 months, investors clearly think it's a good time to be a shareholder -- and that's exactly what's happened to the stock of Madrigal Pharmaceuticals (MDGL 5.53%). Earlier this year, the up-and-coming biotech received approval of a pioneering liver-disease treatment.

3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move

Zacks Investment Research

Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?

Madrigal Pharmaceuticals, Inc. (MDGL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MDGL's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?

Zacks Investment Research

Wall Street Analysts Believe Madrigal (MDGL) Could Rally 26.44%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in Madrigal (MDGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Madrigal (MDGL) Could Rally 26.44%: Here's is How to Trade

Zacks Investment Research

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

The Motley Fool

1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More

There's a bright future ahead for this company.

1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More

See News Rankings

Charts implemented using Lightweight Charts™